Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2021

View Archived Issues

AAV-TNALP-D10 shows potential as one-time-dose treatment in murine model of hypophosphatasia

Cold exposure ameliorates active experimental autoimmune encephalomyelitis

Takinib inhibits STAT3 activation and shows promise for treating rheumatoid arthritis

IL-40 is upregulated in rheumatoid arthritis and decreases following depletion therapy

Targeting NNMT as novel therapeutic strategy for fibrotic diseases

Sumitomo Dainippon Pharma patents new compounds for epilepsy

Roche discloses GABA-A receptor PAMs

Taiho Pharmaceutical presents new GTPase KRAS mutant inhibitors

Plexxikon identifies new CD73 inhibitors

C4X Discovery Holdings patents NFE2L2 activators

BioArctic developing antibody treatments targeting TDP-43 for ALS

Enhancing endothelial cell S1PR1 signaling attenuates arthritis in vivo

CPI-381: a first-in-class TREX1 inhibitor with antitumor activity in preclinical models

BAY-56-6544 improves vasomotor function in accelerated-aging model

Rat model mimics the features of cerebral small vessel disease

Soluble ACE2 decoy peptide ameliorates SARS-CoV-2 lung vascular injury

AASLD meeting: Cholangiocytes can induce liver regeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...